Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[A case of hepatic sarcoidosis presenting with cirrhotic symptoms].
Kaji K, Ogino H, Hirai S, Shimatani A, Horita Y, Matsuda K, Hiramatsu K, Matsuda M, Shimizu K, Nakanishi Y, Noda Y. Kaji K, et al. Among authors: horita y. Nihon Shokakibyo Gakkai Zasshi. 2014 Mar;111(3):557-65. Nihon Shokakibyo Gakkai Zasshi. 2014. PMID: 24598101 Japanese.
Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
Tsuburaya A, Sugimoto N, Imamura H, Nishikawa K, Imamoto H, Tsujinaka T, Esaki T, Horita Y, Kimura Y, Fujiya T, Takayama O, Oono R, Yabusaki H, Taguri M, Morita S, Yamada Y, Tan P, Ninomiya M, Furukawa H, Sasako M. Tsuburaya A, et al. Among authors: horita y. Clin Oncol (R Coll Radiol). 2016 Aug;28(8):e45-51. doi: 10.1016/j.clon.2016.04.001. Epub 2016 Apr 30. Clin Oncol (R Coll Radiol). 2016. PMID: 27142170 Clinical Trial.
A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
Akiyoshi K, Hamaguchi T, Yoshimura K, Takahashi N, Honma Y, Iwasa S, Takashima A, Kato K, Yamada Y, Onodera H, Takeshita S, Yasui H, Sakai G, Akatsuka S, Ogawa K, Horita Y, Nagai Y, Shimada Y. Akiyoshi K, et al. Among authors: horita y. Clin Colorectal Cancer. 2018 Mar;17(1):e83-e89. doi: 10.1016/j.clcc.2017.10.004. Epub 2017 Oct 16. Clin Colorectal Cancer. 2018. PMID: 29169974 Clinical Trial.
Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX.
Shirasu H, Todaka A, Omae K, Fujii H, Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi N, Hayashi H, Sudo K, Okano N, Horita Y, Kamei K, Yukisawa S, Kobayashi M, Fukutomi A. Shirasu H, et al. Among authors: horita y. Cancer Sci. 2019 Feb;110(2):707-716. doi: 10.1111/cas.13883. Epub 2018 Dec 12. Cancer Sci. 2019. PMID: 30447099 Free PMC article.
FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
Kobayashi N, Omae K, Horita Y, Ueno H, Mizuno N, Uesugi K, Sudo K, Ozaka M, Hayashi H, Okano N, Kamei K, Yamaguchi A, Kobayashi S, Suzuki S, Ishihara S, Uchiyama T, Todaka A, Fukutomi A. Kobayashi N, et al. Among authors: horita y. Pancreatology. 2020 Oct;20(7):1519-1525. doi: 10.1016/j.pan.2020.07.006. Epub 2020 Jul 28. Pancreatology. 2020. PMID: 32972834
186 results